Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.
| MarketCap | 413.9M |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| P/B | |
| P/S (ttm) | |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 0% |
| Held by Institutions % | 22% |
| 1 Day Vol Adjusted Return | 0.7 |
| 1 Month Vol Adjusted Return | 5.2 |
| 3 Month Vol Adjusted Return | 7.4 |
| 6 Month Vol Adjusted Return | 3.7 |
| 20 Days SMA Price ZScore | 1.3 |
| 50 Days SMA Price ZScore | 1.5 |
| 12 -26 Days PPO | 8.3 |
| 1 Month Average Short Volume Ratio | 46.3 |
| 1 Day Volume Change ZScore | -0.3 |
| 1 Month Daily Vol | 6.3 |
Stock news
LONDON and REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 8:00am Eastern Time. A live audio webcast of the presentation can be acc...
LONDON and REDWOOD CITY, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced the closing of its previously announced underwritten public offering of 39,675,000 American Depositary Shares (“ADSs”), at a public offering price of $2.90 per ADS, which includes 5,175,000 additional ADSs issued upon the exercise in full of the underwriters’ option to pu...
LONDON and REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the pricing of an underwritten public offering of 34,500,000 American Depositary Shares (“ADSs”) at a public offering price of $2.90 per ADS. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are exp...
LONDON and REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that it intends to offer and sell American Depositary Shares (“ADSs”) in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or ter...
Companies in the news are: WGO, APOG, MREO, ESTE
Ultragenyx (RARE) and Mereo BioPharma ink an agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta.
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 17) * Acceleron Pharma Inc (NASDAQ: XLRN) * Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) * AtriCure Inc. (NASDAQ: ATRC) * Avanos Medical Inc (NYSE: AVNS) * Bioanalytical Systems, Inc. (NASDAQ: BASI) * BioLife Solutions Inc (NASDAQ: BLFS) * BridgeBio Pharma Inc (NASDAQ: BBIO) * Castle Biosciences Inc (NASDAQ: CSTL) * Certara Ord Shs (NASDAQ: CERT) ...
Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx’s existing bone franchise Ultragenyx leads and funds development to approval; Mereo retains commercial rights in Europe, Ultragenyx commercializes in US and in rest of worldMereo receives $50 million upfront and is eligible for milestones up to $254 million NOVATO, Calif., LONDON, and REDWOOD CITY, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), a bi...